Week 87 Review

Trust a Friday to go and mess up my record breaking attempt. Yesterday's gains were zapped and with OPTI:Optibiotix and JLP:Jubilee Platinum both falling further this week, my potential profits have been hit. However, despite Friday's attempts to mess things up, the buffer I had for the week was still strong enough to result in an overall gain of £991, taking the combined portfolios £2,493 into the black with an overall value of £63,716.

I do believe a gap is starting to appear...

Worst performance and only double-digit loser this week was OPTI:Optibiotix, which dropped 10%. I suspect this was mostly down to existing holders selling their shares in order to buy the spin-off SBTX:SkinBioTherapeutics. It battered my potential profits though.

Not double digits, but JLP:Jubilee Platinum fell 8% and also crippled my potential profits, so it's all the more remarkable that everything is up by £991 at the end of the week.

That increase is thanks to a host of great performers. IQE:IQE wasn't double digit, but 8% was very nice. The first double-digit riser was SBTX:SkinBioTherapeutics which rose 13% and vindicated my decision to buy early. It has already wiped out the £90 loss I took to sell VEC:Vectura to raise the cash.

Next great performance was CAML:Central Asia Metals which has been slipping for no real reason lately, but climbed 22% this week to recover nearly all the recent losses.

Star Share was KIBO:Kibo Mining, which was absolutely soaring all week and went from £1,500 loss last week to £245 profit on Thursday. Tragically there was a re-trace today and it dropped 7.5% and back to a £280 loss. Hopefully that was just profit taking and the sentiment that has driven the share in the early part of the week will return next week.

Here's the ISA and share accounts performance

			Weekly Change
Portfolio cost	£42,964.02		-£92.97
Portfolio sell value (bid price - commission)	£42,193.30	(-1.8%)	+£314.91
Potential profits	£4,082.42		-£583.43
Yr 2 Dividends	£357.10		+£0
Yr 2 Profit from sales	£3,314.79		-£89.44
Yr 2 Average monthly cash profit	£451.37		-£24.67
Yr 2 Avg annual % of current portfolio cost	12.6%
Total Dividends	£1,025.03		+£0
Total Profit from sales	£7,155.05		-£89.44
Average monthly cash profit	£403.12		-£9.20
(Sold stocks profit + Dividends - Fees / Months)
Avg annual % of current portfolio cost	11.3%

The sale of VEC:Vectura for a £89.44 loss meant the portfolio cost dropped when I bought SBTX:SkinBioTherapeutics, as it was 5th April and I couldn't top up the ISA any more. This affected the average monthly performance too, with bigger drops than usual. I had hoped to bed AMYT:Amryt Pharma and JLP:Jubilee Platinum into my ISA today, but for some reason Hargreaves Lansdown didn't process the order so I cancelled it this evening. I don't want to risk something happening over the weekend that causes massive volatility in the market next week, and let's face it, there's a reasonably good chance of it!

The potential profits were hammered, losing £583 with the drops in OPTI:Optibiotix and JLP:Jubilee Platinum. Most of the improvement that allowed the portfolio value to go up was KIBO:Kibo Mining reducing losses.

It was probably a bit too much to hope for that the green line would meet the red this week. It came so close yesterday, but the gap is only £770 so a recovery in the shares that fell this week could fill that gap quickly.

I've removed the trend lines from the graphs - I decided they didn't really add much and were making it harder to see what was going on.

The SIPP looks like this after week 71

			Weekly Change
Portfolio cost	£16,776.69		+£0
Portfolio sell value (bid price - commission)	£20,138.00	(+20%)	+£506.61
Potential profits	£3,950.30		+£496.41
Yr 2 Dividends	£0		+£0
Yr 2 Profit from sales	£842.07		+£0
Yr 2 Average monthly cash profit	£185.67		-£10.31
Yr 2 Avg annual % of current portfolio cost	13.3%
Total Dividends	£413.19		+£0
Total Profit from sales	£3,191.93		+£0
Average monthly cash profit	£215.23		-£3.07
(Sold stocks profit + Dividends - Fees / Months)
Avg annual % of current portfolio cost	15.4%

A really good week for the SIPP, mainly thanks to CAML:Central Asia Metals rising 22% and IQE:IQE performing well. That allowed the OPT:Optibiotix and JLP:Jubilee Platinum drops to be swallowed up. Just imagine what a week it would have been if they hadn't dropped!

Back to a widening habit - good to see.

The trading portfolio now looks like this

			Weekly Change
Portfolio cost	£1,481.98		+£0
Cash	£79.63		+£0
Portfolio sell value (bid price - commission)	£1,385.03	(-6.5%)	+£169.65
Potential profits	£0		+£0
Dividends	£0		+£0
Profit from sales	£61.57		+£0
Average monthly cash profit	£7.21		-£0.20
(Sold stocks profit + Dividends - Fees / Months)
Avg annual % of current portfolio cost	5.8%

A good week for a change, mainly thanks to KIBO:Kibo Mining going into profit. I wish I'd sold them on Thursday before the 7.5% drop - must remember this account is meant to be for quick gains, not long term investing. I think I'll avoid selling shares in this account as a live transaction, but when they get to the price I want, I'll put a fairly tight stop-loss on them so I can follow them up if they continue to climb.

There is one thing I have to do with this account, which is get back the third £500 I added. My car cost £800 to get through its MOT today, on the same day I paid a £1,250 deposit on a holiday. The £500 has to plug some of that hole, so when I sell Kibo next week, I'll keep the profit in the account but take out the £500.

Looking much more healthy, and if I'd taken the snapshot yesterday the lines would have crossed

So as usual, as some shares recover others fall. Given all the goings on this week, I'm very pleased with the performance. SBTX:SkinBioTherapeutics has exceeded expectations following IPO and OPTI:Optibiotix CEO Steve O'Hara said that he would consider returning value to shareholders following the spin-off once the shares were up by 20-30%. Well they floated at 9p and are now at 16.25p which I make 80%. That's a lot of profit to Optibiotix who own half the shares. That's why it's a mystery the Optibiotix share price tanked 10% this week.

Let's see how the story unfolds...

SkinBioTherapeutics day 2

Great news on day 2, with SBTX:SkinBioTherapeutics climbing 10.4% and into a small profit of £21.

There were only 2.6 million trades today, so far fewer than day 1.

I promise not to report on this every day - but it's the first time I've been invested in a brand new company so I'm excited. I suspect it will wear off by tomorrow.

On checking the trades from yesterday, I discovered I was the 8th person to buy, at 08:00:46hrs. The first person shouldn't count as that was before 8am, so I think I should qualify as the 7th person to buy on the open market.

I'm hoping in 10 years time I'll be able to look back with nostalgia as I explain why the shares that are worth £10 each have made me so much money on a £1,000 investment. That's my daydream anyway.

Elsewhere in the portfolio, today has been spectacular once again, and the combined accounts are £1,670 up this week, which would be a record if it can be sustained to the end of tomorrow. They are now £3,173 in the black and the dreaded ISA and share portfolios are only £232 from break-even. Is it too much to hope that tomorrow will see the green line overtake the red?

Today's £700 climb was largely down to KIBO:Kibo Mining climbing 15.2% and going back into profit of £245. Not bad from a £1,500 loss last week! Ah - the joys of AIM shares. The other big riser was CAML:Central Asia Metals which climbed 4.3% and that's worth a lot.

OPTI:Optibiotix continues to drip slowly downwards, with another 1p gone today and only 2p away from returning to loss. JLP:Jubilee Platinum didn't drop any more today, but is still less than 5p which is a surprise and disappointment.

IQE:IQE finally gave up the relentless climb and dropped 2.7% today, so maybe the dream is over for a while. Not that long ago I would have banked the £3,000 profit, but this one's for the long haul.

So a great day despite some of the big shares having a bad or at least indifferent time.

Fridays have a habit of spoiling a good week, so I wouldn't be surprised if tomorrow has a sting in the tail, but there's a £1,600 buffer on the week performance, so it would have to be a very painful sting to be a spoiler...

SkinBioTherapeutics day 1

A nervous day watching the share price of SBTX:SkinBioTherapeutics today.

My biggest fear was a tank back to the IPO price of 9p following my purchase at 8:01am.

I bought 7,486 shares at 13.9p costing £1,052.50 and with the bid price at 10p was immediately losing £300 on paper.

Fortunately the price settled for much of the day at 13.5p bid and 14p offer, so I was feeling fairly smug that I had got in cheap.

Unfortunately it dropped right at the end of the day to 13p bid and 13.5p offer, so if I'd waited a bit longer I would have been able to buy more.

I don't care really, in fact I'm made up that I would have been one of the first people to buy shares in this company on the open market. It was literally seconds after 8am.

There were 9.8 million shares traded today, which is quite spectacular. It will be very interesting to see how many are traded tomorrow, as people will be filling their ISAs at the start of the new tax year.

I'm planning on bedding some of my share account holdings into my ISA, with the main candidates 6,882 AMYT:Amryt Pharma and 81,087 JLP:Jubilee Platinum. I have high hopes that both these shares will perform well over the next few years, so sheltering them from tax will be a good thing.

It will have an odd effect on my stats. AMYT:Amryt Pharma is £102.23 in profit and JLP:Jubilee Platinum is £377.67 in profit, so it will boost my monthly performance figure, but will lose me £480 from my paper profits.

Fortunately it's been another good day overall, with KIBO:Kibo Mining climbing 9.5% and reducing my paper losses to about £450, which is about £1,000 better off than last week. Amazingly IQE:IQE went up even more, and is now £3,270 in profit. Another big gainer today was REDS:RedstoneConnect, climbing 12.1% after news of a new contract. I've only got this in my trading account, but am becoming increasingly interested as a potential long-term holding.

So the combined portfolio is up by £924 for the week and £2,427 in the black, with the combined ISA and share accounts only £769 in the red and perilously close to break-even. The overall portfolio value has gone over £63,000 so I'm allowed a "Woohoo!".

All eyes on the start of the tax year tomorrow, and will SBTX:SkinBioTherapeutics maintain its value?

SkinBioTherapeutics in the bag

I was poised on the buy button at 1 second past 8 this morning in my quest for SBTX:SkinBioTherapeutics shares.

First press of the button and no quote available. Second quote also not available.

Third press of the button 15p - bugger - oh well, that was the maximum I was prepared to spend so I pressed buy.

Message came back - sale could not be processed - bugger!!

Hit the re-quote button again

Offer came back at 13.9p - yippee!!

Hit the buy button and this time it went through.

Initial feeling of relief and satisfaction.

Soon followed feelings of worry - the IPO price was 9p. Have I paid chronically over the odds?

Massive 30% spread so the holding was losing £300 immediately.

It seems to have settled down now, with a bid price of 13.5p meaning my loss is only £48, and offer price of 14.5p.

All I can do is watch now and see how it ends the day...

All ready for SkinBioTherapeutics Launch

VEC:Vectura ticked up a little today, so my loss was reduced to £89.44 (7.3%) when I sold them at lunchtime, but it means I have £1,052.58 ready to invest in SBTX:SkinBioTherapeutics first thing in the morning.

I'm rather nervous about the event. How far will the price have climbed in the first few seconds of trading? Will I even be able to buy on-line? Will I only be able to place a limit order? What's the maximum I'm willing to pay?

So many questions. I was bitten by getting over-excited when I first found out about OPTI:Optibiotix, and bought loads for 90p, which would still be loss-making if I hadn't topped up so many at prices all the way down to 68p. I don't want to make that mistake again, and buy at an inflated price early, only to find it drops 30% for a year.

I think I'll aim for 12p, and if it goes higher then I'll put in a limit order at 12p and see what happens. I can always buy more JLP:Jubilee Platinum in the short term, as that's dropped to a stupid price today, so could be somewhere to rest my money until SBTX:SkinBioTherapeutics sorts itself out. There's just that risk that it will continue to climb and I'll miss my opportunity.

Having said that, OPTI:Optibiotix only had 42 trades all day today, and amazingly most were sells - the day before holders may qualify for free shares in SkinBioTherapeutics! I guess they don't believe we will get free shares. Must admit, I'm beginning to doubt it myself. I just can't believe they would give away 25% of our company without some form of compensation.

Meanwhile it's been another great day today.

CAML:Central Asia Metals issued a superb final results statement, with record output and an increased dividend. What a superb company! The share price went up 5% which was worth hundreds of pounds.

KIBO:Kibo Mining is finally waking up. I don't know whether it's improved sentiment following the UK Investor Show at the weekend, or if news is imminent, but the bid price has gone from 4p to 5p in 2 days and wiped out a big chunk of my losses. They now sit at £814.15 which means Kibo is no longer my Nemesis Share. That title returns to AFG:Aquatic Food and may stay there for a while, as I think only news of buying another company could possibly make this share move.

IQE:IQE never fails to disappoint, climbing another 6.6% and now standing at a potential profit of £3,119.62. The most any share I have ever owned has been in profit. How much further can it go?

That leaves the combined portfolios up £773.43 on the week and £2,275 in the black overall. The ISA and share accounts are now only £828 in the red! Could they finally get into profit? Last time they got this close Trump appeared and everything plummeted, so I will try to temper my excitement.

So, I must steel myself for the morning, finish my daily constitutional a few minutes early and make sure I'm sat at my PC just before 8am so I can be poised to pounce!

Week 86 Review

A great week. Some shares made significant progress, breaking out of previous tight ranges like AMYT:Amryt Pharma and OPTI:Optibiotix, or issuing transformational news like JLP:Jubileee Platinum, despite the share price not yet reflecting that news. There was some disappointment too, with KIBO:Kibo Mining continuing to fall and having a significant impact on the portfolio value. The good news is that the combined portfolios ended up £654.34 better off than last week and they are £1,502.46 in the black with a combined value of £62,818.13.

Worst performer this week was BLUR:Blur Group dropping 11%, but that's of no matter as my shares are practically worthless anyway.

More distressing was the 10% drop in KIBO:Kibo Mining. I really don't understand the negative sentiment towards this share. The bulletin board is crawling with complete lunatics trying their illiterate best to drive the share price down, and normally that's a sign it's about to surge. I really hope so as it's now £1,524.91 in the red and by far my Nemesis Share. Given that a few weeks ago OPTI:Optibiotix was my Nemesis Share with similar losses, but is now £1,116.46 in profit, there's always hope!

Share of the Week was AMYT:Amryt Pharma, climbing 12% and being a major contributor to this week's good performance. The world is waking up to the promise in this company, so I'm confident this is just the start.

Here's the performance of the combined ISA and share accounts

			Weekly Change
Portfolio cost	£43,056.99		+£0
Portfolio sell value (bid price - commission)	£41,971.36	(-2.5%)	+£782.53
Potential profits	£4,665.85		+£966.35
Yr 2 Dividends	£357.10		+£0
Yr 2 Profit from sales	£3,404.23		+£0
Yr 2 Average monthly cash profit	£476.04		-£14.42
Yr 2 Avg annual % of current portfolio cost	13.3%
Total Dividends	£1,025.03		+£0
Total Profit from sales	£7,244.49		+£0
Average monthly cash profit	£412.32		-£4.85
(Sold stocks profit + Dividends - Fees / Months)
Avg annual % of current portfolio cost	11.5%

£966 increase in potential profits is wonderful, with KIBO:Kibo Mining the main cause of the portfolio value only climbing by £782. Nothing else happened so a slight tick down on average performance.

That looks so good - a stunning beauty to behold! These accounts have never, ever been in the black. The closest was between weeks 58 and 59 where the deficit was £472. We're still a way off that, with £1,085 difference, but a few more weeks like this one would remove that. The moral of the story is "Don't panic!".

The SIPP looks like this after week 70

			Weekly Change
Portfolio cost	£16,776.69		+£0
Portfolio sell value (bid price - commission)	£19,631.39	(+17.0%)	-£46.19
Potential profits	£3,453.89		-£18.05
Yr 2 Dividends	£0		+£0
Yr 2 Profit from sales	£842.07		+£0
Yr 2 Average monthly cash profit	£195.98		-£11.53
Yr 2 Avg annual % of current portfolio cost	14.0%
Total Dividends	£413.19		+£0
Total Profit from sales	£3,191.93		+£0
Average monthly cash profit	£218.30		-£3.17
(Sold stocks profit + Dividends - Fees / Months)
Avg annual % of current portfolio cost	15.6%

The 6% increase in OPTI:Optibiotix was wiped out by a 6% loss in CAML:Central Asia Metals and 3% drop in ARL:Atlantis Resources. Central Asia Metals has dropped so much recently that it's looking like a good time to add more. Preliminary results are due out on Tuesday and if a healthy dividend is announced, the recent dip could be history.

Steady as she goes...

The trading account looks like this after week 36

			Weekly Change
Portfolio cost	£1,481.98		+£495.96
Cash	£79.63		+£4.04
Portfolio sell value (bid price - commission)	£1,215.38	(-18.0%)	-£81.98
Potential profits	£0		+£0
Dividends	£0		+£0
Profit from sales	£61.57		+£0
Average monthly cash profit	£7.41		-£0.21
(Sold stocks profit + Dividends - Fees / Months)
Avg annual % of current portfolio cost	6.0%

What's this? I had an unexpected windfall from a delayed flight compensation payment. In theory I should have put it towards the deposit for my next holiday, but I've already put that aside, so I thought seeding another £500 into this account might perk it up a bit.

I purchased 9,120 shares in JLP:Jubilee Platinum at 5.34p costing £495.96. I couldn't stand by and watch the share price at this value and not do something. There was so much amazing news this week and last week that I really expected the price to have topped 10p by now. It feels like a volcano swelling, incapable of holding everything in for much longer. When it goes, I think it's going to be spectacular. A surge to 10p would take the market cap past £100m and into the sight of the institutional investors, then there's no stopping it. I want to keep my existing 150,000 shares for the long haul, as I am expecting £1 a share in a few years. This purchase will be to take advantage of the imminent eruption. Or of course, I could be completely wrong...

The other shares in this account did dreadfully so the overall performance is shocking.

Another neat step upwards for cost, and a further widening of the gap for a green line that's spent virtually the whole time below the red.

So, another amazingly exciting week has passed. What is there to look forward to next week?

As mentioned above, preliminary results from CAML:Central Asia Metals could be good news if the dividend is increased. JLP:Jubilee Platinum are on a roll and I'm almost expecting another great RNS every day. KIBO:Kibo Mining surely can't keep dropping so badly, so I'm keeping fingers crossed for something to reverse the drop, and the birth of Katoro Mining could just do that.

All this fades into insignificance compared to the big event on Wednesday - the IPO of SkinBioTherapeutics. My sacrificial shares will be VEC:Vectura which are making a 7% loss, but will liberate £1,062 so I can be there from the start. My worry is that the demand will be so high that I can't buy them quick enough and the price zooms above what I'm willing to pay. What's frustrating is that I wouldn't bother if I knew what was going on with existing OPTI:Optibiotix holders and whether we get free shares. I think we ought to, but there has been no announcement. I'll hold off selling Vectura until the last possible minute in the hope we get some news. Otherwise, Wednesday morning could be a bit fraught...

Jubilee is a platinum producer!

The most important RNS yet for JLP:Jubilee Platinum, which up till now should only have been called Jubilee Chrome. This RNS has inserted the Platinum. It's been an 18 month wait since I invested, but it's worth it. The shares rocketed by 9.2% in the last 2.5 hours of trading after the news was published. The 5.55p bid price puts potential profit at £1,821 but it doesn't get a chance to re-take Star Share as IQE:IQE won't stop going up, and is at £2,514 potential profit.

I do have one slight concern, with interim results due out this week covering a period before any platinum was produced, and when chromite production at ASA was reduced in order to build new capacity for platinum enriched tailings storage. Any excuse for these shares to drop back to 5p seems to be embraced with open arms!

With gains this week from AMYT:Amryt Pharma too, things are going quite well. KIBO:Kibo Mining is determined to spoil things though, dropping even further to go £1,347 into loss and firmly consolidate the position of Nemesis Share.

The effect on the combined portfolios is an increase of £752 on last week and the portfolios £1,600 in the black. The combined ISA and share accounts have never been in the black on their own, but are now only 4.3% down. It's the SIPP being up 17.3% that's keeping the combined figure above water. We won't mention the 18.7% deficit in the trading account - that's the black sheep of the accounts but only has £1,000 in it.

There is one massive RNS tomorrow which is the AMYT:Amryt Pharma results. I don't know which way it will go, but doubt very much is will stay flat. This is such a big share in my portfolio that tiny changes have a huge impact.

If JLP:Jubilee Platinum also post an RNS tomorrow, that is likely to cause a big switch one way or the other too, whereas GVC:GVC Holdings going ex-dividend on a 12.5p divvy will knock at least £80 off the value, unless lots of people happen to buy in on the same day.

Just got to wait and see what happens...